{
    "id": 28957,
    "fullName": "SDCBP over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SDCBP over exp indicates an over expression of the Sdcbp protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6386,
        "geneSymbol": "SDCBP",
        "terms": [
            "SDCBP",
            "MDA-9",
            "MDA9",
            "ST1",
            "SYCL",
            "TACIP18"
        ]
    },
    "variant": "over exp",
    "createDate": "11/24/2018",
    "updateDate": "11/24/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15231,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) treatment of TNBC cell lines overexpressing Sdcbp prevented Src phosphorylation and subsequent cell proliferation (PMID: 28141839).",
            "molecularProfile": {
                "id": 30878,
                "profileName": "SDCBP over exp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12938,
                    "pubMedId": 28141839,
                    "title": "Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28141839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30878,
            "profileName": "SDCBP over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}